Equities

Candel Therapeutics Inc

CADL:NMQ

Candel Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)4.47
  • Today's Change-0.18 / -3.87%
  • Shares traded357.89k
  • 1 Year change+395.02%
  • Beta-0.9407
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments357083
Total Receivables, Net------
Total Inventory------
Prepaid expenses1.381.892.30
Other current assets, total------
Total current assets377285
Property, plant & equipment, net4.025.483.84
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets0.12----
Total assets417889
LIABILITIES
Accounts payable0.420.381.59
Accrued expenses4.875.193.44
Notes payable/short-term debt000
Current portion long-term debt/capital leases8.89----
Other current liabilities, total00.050.33
Total current liabilities145.625.36
Total long term debt12210.56
Total debt21210.56
Deferred income tax------
Minority interest------
Other liabilities, total1.893.5119
Total liabilities283025
SHAREHOLDERS EQUITY
Common stock0.290.290.29
Additional paid-in capital150147144
Retained earnings (accumulated deficit)(137)(99)(80)
Treasury stock - common(0.45)(0.45)--
Unrealized gain (loss)------
Other equity, total------
Total equity134864
Total liabilities & shareholders' equity417889
Total common shares outstanding292929
Treasury shares - common primary issue0.120.120
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.